PBM Integration: Economists Outline Benefits Of Mergers In Senate Hearing
Executive Summary
Recent mergers between PBMs and insurers should address one long-term strategic objective of pharma – the recognition by payors of the value of biopharmaceutical products in relation to other medical costs.
You may also be interested in...
WellCare To Triple Medicare Part D Membership With Purchase Of Aetna Plans
Divestiture prevents CVS from gaining even more dominance in the stand-alone Medicare Part D sector with its acquisition of Aetna, assuming the transaction is cleared by the government.
Health Reform Endgame: Medicare Advantage For All?
The political dynamics of the health care debate are changing again, and now Democrats are likely to return to universal coverage as a high-profile campaign theme. Is there a US “single-payer” model that might actually work out for biopharma innovators?
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.